0JGL.LSE

PCI Biotech Holding ASA

0JGL.LSE, UK

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.

https://www.pcibiotech.com

Stock Price

NOK0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.72

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-46.04 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-31.10 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-954.24 %

Low 5%

High 15%

Debt to Equity

-

High

0.48

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of PCI Biotech Holding ASA

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2022-06-30

EPS Actual

-0.3936

EPS Estimate

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

NOK 0

Cost Of Revenue

NOK 0

Gross Profit

NOK 0

Operating Expenses

NOK 0

Operating Income

NOK 0

Interest Expense

NOK 0

Pretax Income

NOK 0

Net Income

NOK 0

Income Tax Expense

NOK 0

EBITDA

NOK 0

Total Other Income Expense Net

NOK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

NOK 0

Short Term Investments

NOK 0

Receivables

NOK 0

Inventories

NOK 0

Total Current Assets

NOK 0

Property Plant Equipment

NOK 0

Total Assets

NOK 0

Payables

NOK 0

Short Term Debt

NOK 0

Long Term Debt

NOK 0

Total Liabilities

NOK 0

Equity

NOK 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

NOK 0

Depreciation

NOK 0

Change In Working Capital

NOK 0

Cash From Operations

NOK 0

Capital Expenditures

NOK 0

Cash From Investing

NOK 0

Cash From Financing

NOK 0

Net Change In Cash

NOK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.